Adverse events764

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 764

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	[Dose Level I] Pembrolizumab + Trebananib	2	3
other	Anemia	Blood and lymphatic system disorders	[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)	21	40
other	Anemia	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)	5	11
other	Anemia	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)	4	4
other	Lymph node pain	Blood and lymphatic system disorders	[Dose Level I] Pembrolizumab + Trebananib	0	3
other	Lymph node pain	Blood and lymphatic system disorders	[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)	2	40
other	Lymph node pain	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)	0	11
other	Lymph node pain	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)	0	4
other	Thrombotic thrombocytopenic purpura	Blood and lymphatic system disorders	[Dose Level I] Pembrolizumab + Trebananib	0	3
other	Thrombotic thrombocytopenic purpura	Blood and lymphatic system disorders	[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)	1	40
other	Thrombotic thrombocytopenic purpura	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)	0	11
other	Thrombotic thrombocytopenic purpura	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)	0	4
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	[Dose Level I] Pembrolizumab + Trebananib	0	3
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)	1	40
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)	0	11
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)	0	4
other	Chest pain - cardiac	Cardiac disorders	[Dose Level I] Pembrolizumab + Trebananib	0	3
other	Chest pain - cardiac	Cardiac disorders	[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)	1	40
other	Chest pain - cardiac	Cardiac disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)	0	11
other	Chest pain - cardiac	Cardiac disorders	Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)	0	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03239145/events

API reference For AI assistants

Adverse events764

Sources 3

Read this list from software.